New Two-Pronged attack on blood cancer shows promise
NCT ID NCT06572618
Summary
This study is testing a new combination of two drugs, nemtabrutinib and rituximab, for adults with mantle cell lymphoma who have not yet received any treatment. The goal is to see if this two-drug approach can effectively control the cancer by blocking a key protein in cancer cells and helping the immune system attack them. Researchers will measure how well the treatment works and monitor its safety over several years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.